Spherix Reports Findings From New Study in Mice Showing SPX106T Yields Significant Reductions in Serum VLDL

Google Announces Spherix Incorporated

today announced that its drug candidate SPX106T reduced very low-density lipoprotein complexes (VLDLs) by 36% (p=0.05) in the blood of apolipoprotein E-deficient mice consuming a diet containing SPX106T, fat and cholesterol, compared with those consuming one containing sucrose, fat and cholesterol.